MRK Merck and Co Inc

• Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange
• Second-Quarter 2016 GAAP EPS Was $0.43; Second-Quarter Non-GAAP EPS Was $0.93
• Company Updates EPS Guidance: Full-Year 2016 GAAP EPS Range to be Between $1.98 and $2.08; Full-Year 2016 Non-GAAP EPS Range of $3.67 to $3.77
• Advanced KEYTRUDA Development Program
  • KEYTRUDA Demonstrated Superior Progression-Free Survival and Overall Survival Compared to Chemotherapy in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Expressed PD-L1 in KEYNOTE-024 Study
  • Merck Received Positive Opinion from Committee for Medicinal Products for Human Use of the European Medicines Agency for KEYTRUDA for the Treatment of Previously Treated Advanced NSCLC in Patients Whose Tumors Express PD-L1

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2016.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160729005318/en/

“Our results this quarter reflect our strategic focus on key launches, including KEYTRUDA and ZEPATIER, as well as our priority inline programs,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “We remain committed to advancing our pipeline, delivering a balanced and differentiated portfolio, and achieving long-term, sustainable growth.”

 

Financial Summary

      $ in millions, except EPS amounts Second Quarter 2016   2015   Sales $9,844 $9,785 GAAP EPS 0.43 0.24

Non-GAAP EPS that excludes items listed below1

0.93 0.86

GAAP net income2

1,205 687

Non-GAAP net income that excludes items listed below1,2

  2,587   2,441  

Worldwide sales were $9.8 billion for the second quarter of 2016, an increase of 1 percent compared with the second quarter of 2015, including a 2 percent negative impact from foreign exchange.

GAAP (generally accepted accounting principles) earnings per share (EPS) were $0.43 for the second quarter. Non-GAAP EPS of $0.93 for the second quarter excludes acquisition- and divestiture-related costs and restructuring costs.

Pipeline Highlights

In the second quarter of 2016, the company advanced its late-stage pipeline in multiple priority areas and executed on key launches, including KEYTRUDA (pembrolizumab), an anti-PD-1 therapy for the treatment of metastatic NSCLC in previously treated patients whose tumors express PD-L1, as well as advanced melanoma; and ZEPATIER (elbasvir and grazoprevir), a once-daily, fixed-dose combination tablet for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection, with or without ribavirin.

• The company advanced its clinical development program for KEYTRUDA.
  • The company announced topline results from the KEYNOTE-024 trial investigating the use of KEYTRUDA in patients with previously untreated advanced NSCLC whose tumors expressed high levels of PD-L1 (tumor proportion score of 50 percent or more).
    • In this study, KEYTRUDA was superior compared to chemotherapy for the primary endpoint of progression-free survival and the secondary endpoint of overall survival.
    • Based on these results, an independent Data Monitoring Committee recommended that the trial be stopped and that patients receiving chemotherapy in KEYNOTE-024 be offered the opportunity to receive KEYTRUDA.
  • The U.S. Food and Drug Administration (FDA) accepted for review a supplemental Biologics License Application for KEYTRUDA for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. The FDA granted Priority Review with a PDUFA action date of Aug. 9, 2016.
  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of KEYTRUDA for the treatment of locally advanced or metastatic NSCLC in adults whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen.
  • At the 52nd Annual Meeting of the American Society of Clinical Oncology in June, data were presented evaluating the use of KEYTRUDA as a monotherapy and in combination with other therapies in more than 15 different cancers, including melanoma, NSCLC, head and neck cancer, classical Hodgkin lymphoma, multiple myeloma, colorectal cancer and esophageal cancer. Data evaluating KEYTRUDA in new tumor types were presented for the first time in cervical, endometrial, pancreatic, salivary and thyroid cancers.
  • The KEYTRUDA research program includes more than 300 clinical trials evaluating KEYTRUDA across more than 30 tumor types. To date, clinical activity has been shown in more than 20 tumor types.
• Last week, the European Commission approved ZEPATIER for the treatment of chronic HCV in adult patients, allowing marketing of ZEPATIER in all 28 European Union (EU) member states. The company continues to work to supply the EU market, with product launches estimated to begin between the fourth quarter of 2016 and the first quarter of 2017. Product launches are expected to continue across the EU through 2017.
• At the 76th Scientific Sessions of the American Diabetes Association in June, Merck and Pfizer announced that two pivotal Phase 3 studies of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints, showing significant reductions in A1C (a measure of average blood glucose). The companies continue to expect to submit New Drug Applications to the FDA for ertugliflozin as a monotherapy and two fixed-dose combination tablets (ertugliflozin plus JANUVIA [sitagliptin], and ertugliflozin plus metformin) by the end of 2016.

Business Development Highlights

Business development remains a critical component of Merck’s strategy, and the company is actively engaged in seeking external opportunities to complement and strengthen its pipeline and portfolio. The company recently engaged in the following scientific collaborations and acquisitions:

• Earlier this week, the company completed its acquisition of Afferent Pharmaceuticals, a leader in the development of investigational therapeutic candidates for the treatment of common, poorly managed, neurogenic conditions, such as chronic cough.
• The company announced a new collaboration with Moderna Therapeutics to develop and commercialize personalized cancer vaccines, combining KEYTRUDA and Moderna’s messenger-RNA technology.
• Merck Animal Health announced it will acquire a controlling interest in Vallée S.A., a privately held producer of animal health products in Brazil with a portfolio of more than 100 products for livestock, horses and companion animals.

Second-Quarter Revenue Performance

The following table reflects sales of the company’s top pharmaceutical products, as well as total sales of Animal Health products.

                  $ in millions   Second Quarter     Change     Change

Ex-Exchange

2016   2015   Total Sales $9,844 $9,785 1% 3% Pharmaceutical 8,700 8,564 2% 2% JANUVIA / JANUMET 1,634 1,598 2% 2% ZETIA / VYTORIN 994 955 4% 4% GARDASIL / GARDASIL 9 393 427 -8% -7% PROQUAD / M-M-R II / VARIVAX 383 358 7% 10% CUBICIN 357 293 22% 22% REMICADE 339 455 -26% -26% ISENTRESS 338 375 -10% -9% KEYTRUDA 314 110 * * Animal Health 898 840 7% 10% Other Revenues   246   381     -36%     -2%

* >100%

Pharmaceutical Revenue

Second-quarter pharmaceutical sales increased 2 percent to $8.7 billion, reflecting higher sales in oncology, hospital acute care, the cardiovascular franchise and vaccines.

Growth in oncology was driven by higher sales of KEYTRUDA as the company continues to launch the product with new indications globally.

Growth in hospital acute care reflects higher sales of CUBICIN (daptomycin for injection), an I.V. antibiotic, partially due to price increases in the United States, and the U.S. launch of BRIDION (sugammadex) Injection 100 mg/mL, an agent for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults undergoing surgery. In June 2016, the company lost U.S. patent protection for CUBICIN, and, going forward, the company anticipates a significant decline in CUBICIN sales.

Higher sales in the cardiovascular portfolio were primarily driven by an increase in sales of ZETIA (ezetimibe), a medicine for lowering LDL cholesterol, largely due to price increases in the United States, and ADEMPAS (riociguat), a medicine for treating pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, which the company is now promoting and distributing in Europe.

Growth in vaccines resulted largely from higher sales of pediatric vaccines, partially offset by lower sales in the franchise of GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], vaccines to prevent cancers and other diseases caused by HPV, due to the timing of public sector purchases.

Pharmaceutical sales growth also reflects the launch of ZEPATIER, which had sales of $112 million in the quarter.

Second-quarter pharmaceutical sales reflect a decline in REMICADE (infliximab), a treatment for inflammatory diseases, due to the impact of biosimilar competition in the company’s marketing territories in Europe. Pharmaceutical sales also reflect a decrease in sales of NASONEX (mometasone furoate monohydrate), an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, due to loss of exclusivity in the United States.

Animal Health Revenue

Animal Health sales totaled $898 million for the second quarter of 2016, an increase of 7 percent compared with the second quarter of 2015, including a 3 percent negative impact from foreign exchange. Excluding the impact of exchange, sales across all species grew, particularly in products for companion animals, led by BRAVECTO (fluralaner), a chewable tablet that kills fleas and ticks in dogs for up to 12 weeks.

In the second quarter, the company received marketing approval from the EMA for BRAVECTO Spot-On Solution for cats and dogs; last week, the company received approval in the United States to market the product under the tradename BRAVECTO Topical (fluralaner topical solution) for cats and dogs.

Second-Quarter Expense, EPS and Related Information

The tables below present selected expense information.

                  $ in millions  

 

GAAP

 

Acquisition- and Divestiture-Related Costs3

 

Restructuring Costs

 

 

Non-GAAP1

Second-Quarter 2016 Materials and production $3,578 $1,120 $66 $2,392 Marketing and administrative 2,458 18 87 2,353 Research and development 2,151 207 64 1,880 Restructuring costs 134 – 134 –   Second-Quarter 2015 Materials and production $3,754 $1,241 $105 $2,408 Marketing and administrative 2,624 136 17 2,471 Research and development 1,670 71 15 1,584 Restructuring costs   191   –   191   –  

GAAP Expense, EPS and Related Information

On a GAAP basis, the gross margin was 63.7 percent for the second quarter of 2016 compared to 61.6 percent for the second quarter of 2015. The increase for the second quarter of 2016 reflects the favorable impacts of foreign exchange; product mix; lower acquisition- and divestiture-related costs; and lower restructuring costs. Acquisition- and divestiture-related costs and restructuring costs negatively affected gross margin by 12.0 and 13.8 percentage points for the second quarters of 2016 and 2015, respectively.

Marketing and administrative expenses were $2.5 billion in the second quarter of 2016, a 6 percent decrease compared to the second quarter of 2015. The decline reflects lower acquisition- and divestiture-related costs, as well as lower administrative costs, such as legal defense reserves, partially offset by higher restructuring costs.

Research and development (R&D) expenses were $2.2 billion in the second quarter of 2016, a 29 percent increase compared to the second quarter of 2015. The increase primarily reflects higher licensing costs, increased clinical development spending and intangible asset impairment charges.

Other (income) expense, net, was $19 million of expense in the second quarter of 2016 compared to $739 million of expense in the second quarter of 2015. The second quarter of 2015 includes foreign exchange losses of $715 million related to the devaluation of the company’s net monetary assets in Venezuela.

GAAP EPS was $0.43 for the second quarter of 2016 compared with $0.24 for the second quarter of 2015.

Non-GAAP Expense, EPS and Related Information

The non-GAAP gross margin was 75.7 percent for the second quarter of 2016 compared to 75.4 percent for the second quarter of 2015. The increase for the second quarter of 2016 reflects the favorable impacts of foreign exchange and product mix.

Non-GAAP marketing and administrative expenses were $2.4 billion in the second quarter of 2016, a 5 percent decline compared to the second quarter of 2015. The decline reflects lower administrative costs, such as legal defense reserves.

Non-GAAP R&D expenses were $1.9 billion in the second quarter of 2016, a 19 percent increase compared to the second quarter of 2015. The increase primarily reflects higher licensing costs and increased clinical development spending.

Non-GAAP EPS was $0.93 for the second quarter of 2016 compared with $0.86 for the second quarter of 2015.

A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows. Year-to-date results can be found in the attached tables.

      $ in millions, except EPS amounts   Second Quarter 2016   2015 EPS GAAP EPS $0.43 $0.24

Difference4

0.50 0.62

Non-GAAP EPS that excludes items listed below1

$0.93 $0.86   Net Income GAAP net income2 $1,205 $687 Difference 1,382 1,754 Non-GAAP net income that excludes items listed below1,2 $2,587 $2,441   Decrease (Increase) in Net Income Due to Excluded Items: Acquisition- and divestiture-related costs3 $ 1,345 $1,448 Restructuring costs 351 328 Foreign exchange losses related to Venezuela – 715 Net decrease (increase) in income before taxes 1,696 2,491

Income tax (benefit) expense5

(314) (737) Decrease (increase) in net income   $ 1,382   $1,754  

Financial Outlook

Merck has lowered its full-year 2016 GAAP EPS range to be between $1.98 and $2.08, reflecting the impact of intangible asset impairment charges and higher restructuring costs incurred in the second quarter of 2016. The company has raised the bottom end of its full-year 2016 non-GAAP EPS range and is now targeting a range of $3.67 to $3.77, including an approximately 1 percent negative impact from foreign exchange at current exchange rates. The non-GAAP range excludes acquisition- and divestiture-related costs and costs related to restructuring programs.

Merck has narrowed its full-year 2016 revenue range to be between $39.1 billion and $40.1 billion, including an approximately 2 percent negative impact from foreign exchange at current exchange rates.

The following table summarizes the company’s 2016 financial guidance.

            GAAP   Non-GAAP1 Revenue $39.1 to $40.1 billion $39.1 to $40.1 billion** Marketing and administrative expenses Lower than 2015 Lower than 2015 R&D expenses Higher than 2015 Higher than 2015 Effective tax rate 26.0% to 27.0% 21.5% to 22.5% EPS   $1.98 to $2.08   $3.67 to $3.77

** The company does not have any non-GAAP adjustments to revenue.

 

A reconciliation of anticipated 2016 GAAP EPS to non-GAAP EPS and the items excluded from non-GAAP EPS are provided in the table below.

     

$ in millions, except EPS amounts

  Full-Year 2016 GAAP EPS $1.98 to $2.08 Difference4 1.69 Non-GAAP EPS that excludes items listed below1 $3.67 to $3.77   Acquisition- and divestiture-related costs $4,750 Restructuring costs 900 Net decrease (increase) in income before taxes 5,650 Estimated income tax (benefit) expense (955) Decrease (increase) in net income   $4,695  

The expected full-year 2016 GAAP effective tax rate of 26.0 to 27.0 percent reflects an unfavorable impact of approximately 4.5 percentage points from the above items.

Total Employees

As of June 30, 2016, Merck had approximately 68,000 employees worldwide.

Earnings Conference Call

Investors, journalists and the general public may access a live audio webcast of the call today at 8:00 a.m. EDT on Merck’s website at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 34462082. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 34462082. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call.

About Merck

For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn. You can also follow our Twitter conversation at $MRK.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

1 Merck is providing certain 2016 and 2015 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management’s annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the items, see Table 2a attached to this release.

2 Net income attributable to Merck & Co., Inc.

3 Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a result of acquisitions, intangible asset impairment charges and expense or income related to changes in the estimated fair value measurement of contingent consideration. Also includes integration, transaction and certain other costs related to business acquisitions and divestitures.

4 Represents the difference between calculated GAAP EPS and calculated non-GAAP EPS, which may be different than the amount calculated by dividing the impact of the excluded items by the weighted-average shares for the period.

5 Includes the estimated tax impact on the reconciling items. In addition, amount for the second quarter of 2015 includes a net benefit of $370 million related to the settlement of certain federal income tax issues.

  MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1                         GAAP % Change GAAP % Change 2Q16   2Q15

June YTD 2016

 

June YTD 2015

                Sales $ 9,844   $ 9,785 1% $ 19,156   $ 19,210 --   Costs, Expenses and Other Materials and production (1) 3,578 3,754 -5% 7,150 7,323 -2% Marketing and administrative (1) 2,458 2,624 -6% 4,776 5,226 -9% Research and development (1) 2,151 1,670 29% 3,810 3,407 12% Restructuring costs (2) 134 191 -30% 225 273 -18% Other (income) expense, net (1) (3) 19 739 -97% 67 793 -92% Income Before Taxes 1,504 807 86% 3,128 2,188 43% Taxes on Income 295 119 789 542 Net Income 1,209 688 76% 2,339 1,646 42% Less: Net Income Attributable to Noncontrolling Interests 4 1 9 7 Net Income Attributable to Merck & Co., Inc. $ 1,205 $ 687 75% $ 2,330 $ 1,639 42% Earnings per Common Share Assuming Dilution $ 0.43   $ 0.24 79% $ 0.83   $ 0.57 46%             Average Shares Outstanding Assuming Dilution 2,789 2,850 2,792 2,856 Tax Rate (4)   19.6%     14.7%   25.2%     24.8%   (1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.   (2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.   (3) Other (income) expense, net in the second quarter and first six months of 2016 includes a $115 million gain related to settlement of certain patent litigation. Other (income) expense, net in the second quarter and first six months of 2015 includes foreign exchange losses of $715 million to devalue the company's net monetary assets in Venezuela.   (4) The effective income tax rates for the second quarter and first six months of 2015 reflect a net benefit of $370 million related to the settlement of certain federal income tax issues, partially offset by the unfavorable impact of non-deductible foreign exchange losses recorded in connection with the devaluation of the company's net monetary assets in Venezuela.     MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION SECOND QUARTER 2016 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a                     GAAP

Acquisition and Divestiture-Related Costs (1)

Restructuring Costs (2)

Adjustment Subtotal

Non-GAAP     Materials and production $ 3,578 1,120 66 1,186 $ 2,392 Marketing and administrative 2,458 18 87 105 2,353 Research and development 2,151 207 64 271 1,880 Restructuring costs 134 134 134 - Income Before Taxes 1,504 (1,345) (351) (1,696) 3,200 Tax Provision (Benefit) 295 (235) (3) (79) (3) (314) 609 Net Income 1,209 (1,110) (272) (1,382) 2,591 Net Income Attributable to Merck & Co., Inc. 1,205 (1,110) (272) (1,382) 2,587 Earnings per Common Share Assuming Dilution $ 0.43 (0.40) (0.10) (0.50) $ 0.93     Tax Rate   19.6%   19.0%   Only the line items that are affected by non-GAAP adjustments are shown.   Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. Management uses this information internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.   (1) Amounts included in materials and production costs reflect $1.0 billion of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as $95 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions, including severance costs which are not part of the company's formal restructuring programs, as well as transaction and certain other costs related to divestitures. Amounts included in research and development expenses primarily reflect in-process research and development ("IPR&D") impairment charges.   (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.   (3) Represents the estimated tax impact on the reconciling items, based on applying the statutory rate of the originating territory of the non-GAAP adjustments.     MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION SIX MONTHS ENDED JUNE 30, 2016 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b                     GAAP

Acquisition and Divestiture-Related Costs (1)

Restructuring Costs (2)

Adjustment Subtotal

Non-GAAP     Materials and production $ 7,150 2,506 113 2,619 $ 4,531 Marketing and administrative 4,776 20 90 110 4,666 Research and development 3,810 242 119 361 3,449 Restructuring costs 225 225 225 - Income Before Taxes 3,128 (2,768) (547) (3,315) 6,443 Tax Provision (Benefit) 789 (444) (3) (122) (3) (566) 1,355 Net Income 2,339 (2,324) (425) (2,749) 5,088 Net Income Attributable to Merck & Co., Inc. 2,330 (2,324) (425) (2,749) 5,079 Earnings per Common Share Assuming Dilution $ 0.83 (0.84) (0.15) (0.99) $ 1.82     Tax Rate   25.2%   21.0%   Only the line items that are affected by non-GAAP adjustments are shown.   Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. Management uses this information internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.   (1) Amounts included in materials and production costs reflect $2.1 billion of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as $347 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions, including severance costs which are not part of the company's formal restructuring programs, as well as transaction and certain other costs related to divestitures. Amounts included in research and development expenses primarily reflect in-process research and development ("IPR&D") impairment charges.   (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.   (3) Represents the estimated tax impact on the reconciling items, based on applying the statutory rate of the originating territory of the non-GAAP adjustments.   MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) Table 3                                               2016 2015 % Change 1Q   2Q   June YTD 1Q   2Q   June YTD   3Q   4Q   FY 2Q   June YTD TOTAL SALES(1) $ 9,312   $ 9,844   $ 19,156 $ 9,425   $ 9,785   $ 19,210   $ 10,073   $ 10,215   $ 39,498 1   0 PHARMACEUTICAL 8,104   8,700   16,804 8,266   8,564   16,830   8,925   9,027   34,782 2   0 Primary Care and Women's Health Cardiovascular Zetia 612 702 1,314 568 635 1,202 633 691 2,526 11 9 Vytorin 277 293 570 320 320 640 302 308 1,251 -9 -11 Diabetes Januvia 906 1,064 1,970 884 1,044 1,928 1,014 921 3,863 2 2 Janumet 506 569 1,075 509 554 1,063 562 526 2,151 3 1 General Medicine & Women's Health NuvaRing 175 200 376 166 182 348 190 193 732 10 8 Implanon / Nexplanon 134 164 298 137 124 261 176 151 588 32 14 Dulera 113 121 234 130 120 251 133 153 536 1 -7 Follistim AQ 94 73 167 82 111 193 95 95 383 -35 -13 Hospital and Specialty Hepatitis Zepatier 50 112 161 0 0 0 0 0 0 * * HIV Isentress 340 338 678 385 375 760 377 374 1,511 -10 -11 Hospital Acute Care Cubicin(2) 292 357 649 187 293 480 325 322 1,127 22 35 Noxafil 145 143 288 111 117 228 132 128 487 22 26 Cancidas 133 131 263 163 134 297 139 137 573 -2 -11 Invanz 114 143 257 132 139 271 153 144 569 3 -5 Bridion 90 113 204 85 87 172 89 92 353 30 18 Primaxin 73 81 154 65 88 153 75 86 313 -8 1 Immunology Remicade 349 339 688 501 455 956 442 396 1,794 -26 -28 Simponi 188 199 387 158 169 327 178 185 690 18 19 Oncology Keytruda 249 314 563 83 110 192 159 214 566 * * Emend 126 143 268 122 134 255 141 139 535 7 5 Temodar 66 73 139 74 80 155 83 75 312 -9 -10 Diversified Brands Respiratory Singulair 237 229 465 245 212 457 201 273 931 8 2 Nasonex 229 101 331 289 215 504 121 231 858 -53 -34 Other Cozaar / Hyzaar 126 132 258 185 189 374 150 143 667 -30 -31 Arcoxia 111 117 228 123 115 238 123 110 471 2 -4 Fosamax 75 73 148 94 96 190 86 82 359 -24 -22 Zocor 46 50 96 49 63 112 56 49 217 -21 -15 Vaccines Gardasil / Gardasil 9 378 393 770 359 427 785 625 497 1,908 -8 -2 ProQuad / M-M-R II / Varivax 357 383 739 348 358 705 390 409 1,505 7 5 RotaTeq 188 130 318 192 89 281 160 169 610 46 13 Zostavax 125 149 274 175 149 324 179 246 749 0 -15 Pneumovax 23 107 120 228 110 106 216 138 188 542 14 5 Other Pharmaceutical(3) 1,093 1,151 2,246 1,235 1,274 2,512 1,298 1,300 5,105 -9 -11   ANIMAL HEALTH 829 898 1,727 829 840 1,669 825 830 3,324 7 4   Other Revenues(4)   379     246     625   330     381     711     323     358     1,392 -36   -12   * 100% or greater   Sum of quarterly amounts may not equal year-to-date amounts due to rounding.   (1) Only select products are shown.   (2) First quarter of 2015 reflects approximately two months of sales following the acquisition of Cubist Pharmaceuticals, Inc. by Merck on January 21, 2015.   (3) Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were $103 million in the first quarter and $91 million in the second quarter of 2016. Other Pharmaceutical sales were $78 million, $76 million, $99 million and $148 million for the first, second, third and fourth quarters of 2015, respectively.   (4) Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160729005318/en/

MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879